Business Description
Allogene Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US0197701065
Description
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.17 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.28 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.77 | |||||
| Beneish M-Score | -3.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -4.8 | |||||
| 3-Year EPS without NRI Growth Rate | -8.2 | |||||
| 3-Year FCF Growth Rate | 5.4 | |||||
| 3-Year Book Growth Rate | -3.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.14 | |||||
| 9-Day RSI | 42.26 | |||||
| 14-Day RSI | 42.89 | |||||
| 6-1 Month Momentum % | -50.69 | |||||
| 12-1 Month Momentum % | -68.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.58 | |||||
| Quick Ratio | 12.58 | |||||
| Cash Ratio | 12.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.1 | |||||
| Shareholder Yield % | -2.14 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -182224.19 | |||||
| Net Margin % | -178954.3 | |||||
| FCF Margin % | -133951.08 | |||||
| ROE % | -51.94 | |||||
| ROA % | -42.3 | |||||
| ROIC % | -119.97 | |||||
| ROC (Joel Greenblatt) % | -177.25 | |||||
| ROCE % | -46.06 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1235 | |||||
| PB Ratio | 0.71 | |||||
| Price-to-Tangible-Book | 0.71 | |||||
| EV-to-EBIT | -0.12 | |||||
| EV-to-EBITDA | -0.12 | |||||
| EV-to-Revenue | 216.34 | |||||
| EV-to-Forward-Revenue | 804.81 | |||||
| EV-to-FCF | -0.16 | |||||
| Price-to-Net-Current-Asset-Value | 1.2 | |||||
| Price-to-Net-Cash | 1.24 | |||||
| Earnings Yield (Greenblatt) % | -833.33 | |||||
| FCF Yield % | -59.94 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALLO
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Allogene Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.186 | ||
| EPS (TTM) ($) | -2.24 | ||
| Beta | 0.06 | ||
| Volatility % | 55.05 | ||
| 14-Day RSI | 42.89 | ||
| 14-Day ATR ($) | 0.252586 | ||
| 20-Day SMA ($) | 2.61575 | ||
| 12-1 Month Momentum % | -68.15 | ||
| 52-Week Range ($) | 2.23 - 9.06 | ||
| Shares Outstanding (Mil) | 168.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Allogene Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Allogene Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Allogene Therapeutics Inc Frequently Asked Questions
What is Allogene Therapeutics Inc(ALLO)'s stock price today?
The current price of ALLO is $2.47. The 52 week high of ALLO is $9.06 and 52 week low is $2.23.
When is next earnings date of Allogene Therapeutics Inc(ALLO)?
The next earnings date of Allogene Therapeutics Inc(ALLO) is 2024-02-28 Est..
Does Allogene Therapeutics Inc(ALLO) pay dividends? If so, how much?
Allogene Therapeutics Inc(ALLO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers